Table 1 Prognostic role of EZH2 in diverse cancers through OncoLnc
From: The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
Cancer | Cox | P-value | FDR | Rank | Median | Mean |
|---|---|---|---|---|---|---|
BLCA | 0.032 | 7.00e-01 | 8.58e-01 | 13,285 | 475.71 | 599.61 |
BRCA | 0.082 | 3.50e-01 | 7.03e-01 | 8182 | 395.74 | 504.19 |
CESC | − 0.327 | 1.60e-02 | 2.05e-01 | 1239 | 1033.8 | 1118.51 |
COAD | − 0.147 | 1.50e-01 | 5.58e-01 | 4290 | 657.07 | 697.51 |
ESCA | 0.001 | 9.90e-01 | 9.95e-01 | 16,624 | 482.73 | 573.25 |
GBM | − 0.037 | 6.90e-01 | 9.58e-01 | 12,003 | 598.43 | 689.2 |
HNSC | − 0.158 | 2.40e-02 | 2.46e-01 | 1590 | 479.81 | 577.87 |
KIRC | 0.292 | 2.30e-04 | 1.62e-03 | 2346 | 126.98 | 149.04 |
KIRP | 0.527 | 7.90e-04 | 8.76e-03 | 1477 | 123.29 | 140.76 |
LAML | − 0.028 | 8.20e-01 | 9.43e-01 | 13,200 | 1041.46 | 1043.88 |
LGG | 0.277 | 6.20e-03 | 1.62e-02 | 6414 | 216.22 | 286.97 |
LIHC | 0.478 | 2.80e-06 | 1.23e-03 | 36 | 248.55 | 306.71 |
LUAD | 0.097 | 1.80e-01 | 4.10e-01 | 7248 | 320.93 | 397.7 |
LUSC | − 0.088 | 1.90e-01 | 7.01e-01 | 4467 | 629.89 | 713.28 |
OV | − 0.003 | 9.70e-01 | 9.93e-01 | 16,448 | 503.56 | 601.14 |
PAAD | 0.228 | 4.10e-02 | 1.63e-01 | 4299 | 207.07 | 238.52 |
READ | − 0.188 | 3.80e-01 | 9.57e-01 | 6463 | 643.34 | 675.6 |
SARC | 0.133 | 2.00e-01 | 4.83e-01 | 6586 | 440.14 | 578.62 |
SKCM | 0.052 | 4.40e-01 | 6.36e-01 | 11,030 | 447.42 | 528.58 |
STAD | − 0.169 | 5.30e-02 | 3.49e-01 | 2548 | 483.32 | 521.53 |
UCEC | 0.121 | 3.00e-01 | 9.88e-01 | 4955 | 460.41 | 528.01 |